Choi YH, et al. - In this randomized, double-blind, placebo-controlled trial, 97 candidates were estimated to assess the anti-cancer activity of oral curcumin in subjects with prostate cancer who received intermittent androgen deprivation (IAD). Authors noticed significant lower proportion of candidates with PSA progression in the curcumin group as compared to the placebo group. The incidence of adverse events was higher in the placebo group. Between the two groups, no significant variations were noted in the adverse drug reaction. They suggested curcumin consumption safe and well-tolerated although it did not significantly affect the overall off-treatment span of IAD.